

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

#### **(1) RE-DESIGNATION OF DIRECTOR AND APPOINTMENT OF CHIEF EXECUTIVE OFFICER;**

**AND**

#### **(2) APPOINTMENT OF CHIEF FINANCIAL OFFICER**

The Board announces that with effect from 21 October 2025:

- (1) Mr. Zhang Ming Qi has been re-designated from a non-executive Director to an executive Director and appointed as the Chief Executive Officer; and
- (2) Mr. Che Kean Tat has been appointed as the Chief Financial Officer.

#### **RE-DESIGNATION OF DIRECTOR AND APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (“**Director(s)**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. ZHANG Ming Qi (張鳴琪) (“**Mr. Zhang**”) has been re-designated from a non-executive Director to an executive Director (the “**Re-designation**”) and appointed as the chief executive officer of the Company (the “**Chief Executive Officer**”), all with effect from 21 October 2025.

Biographical details of Mr. Zhang are summarised below:

Mr. Zhang, aged 32, has extensive expertise and experience in investment banking services and financial investments. From 2016 to 2020, he held progressive roles as investment associate, investment manager and senior financial advisor in C.V. Starr & Co., Inc., New York, the United States, where he was in charge of advising clients on international business development strategies including but not limited to fundraising and deal structuring as well as facilitating cross-border acquisitions of U.S.-China core assets for global investment funds. From 2020 to 2022, he served as a director of institutional business of Beijing Hande Donghui Asset Management Co., Ltd., a Warburg Pincus controlled distressed assets and alternative investment fund where he

managed investment and financing initiatives for domestic and international distressed asset funds. Since February 2023, he has been serving as a managing director and the head of institutional business of Pillar Capital, where he oversees investments, financing and disposal activities related to, among others, distressed assets and distressed financing, and manages regional team operations. He was appointed as a non-executive Director since 23 June 2025.

He obtained a bachelor's degree in Applied Mathematics and Economics at University of Wisconsin-Madison in 2015. He then obtained a master's degree in Mathematical Finance at Boston University Questrom School of Business.

In respect of the Re-designation, Mr. Zhang has entered into a new service contract with the Company to replace the existing letter of appointment entered into with the Company in respect of his initial appointment as a non-executive Director for the remaining term of three years commencing from 23 June 2025, subject to retirement by rotation and re-election at the next following annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Zhang is entitled to a director's fee of HK\$100,000 per month for his position as an executive Director, which was determined with reference to the prevailing market conditions, his experience and his duties and responsibilities on the Company's affairs. All the director's fee to be received by Mr. Zhang is covered by the Service Contract. Mr. Zhang's Service Contract can be terminated by giving one month's notice in writing.

Mr. Zhang has also entered into an employment contract with the Company in relation to his position as the Chief Executive Officer ("**Mr. Zhang's Employment Contract**"), which has no fixed term but can be terminated by either party upon giving to the other party 1 month's prior written notice with effect from 21 October 2025. Pursuant to Mr. Zhang's Employment Contract, Mr. Zhang will be entitled to a salary of HK\$100,000 per month which was determined with reference to his background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions and discretionary bonus(es). The amount of the discretionary bonus(es) will be determined by the Board upon recommendation from the remuneration committee of the Board, having regard to, among other things, the performance of Mr. Zhang and the overall performance of the Group.

Save as disclosed above, Mr. Zhang has confirmed that, as at the date of this announcement, he (i) has not held any other directorships in the last three years preceding the date of this announcement in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold other position with the Company and other members of the Group; (iii) has no other major appointments and professional qualifications; (iv) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, there are no other matters concerning the Re-designation and appointment of Chief Executive Officer that need to be brought to the attention of the shareholders of the Company, and there is no other matter which shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Board would like to express its warm welcome to Mr. Zhang on the Re-designation and his appointment as the Chief Executive Officer.

#### **APPOINTMENT OF CHIEF FINANCIAL OFFICER**

The Board is pleased to announce that Mr. Che Kean Tat (徐建達) (“**Mr. Che**”) will be appointed as the chief financial officer of the Company (the “**Chief Financial Officer**”) with effect from 21 October 2025.

Biographical details of Mr. Che are summarised below:

Mr. Che, aged 42, has over 20 years of experience in accounting, auditing, corporate finance and IPO advisory. In 2005, he started his career as auditor with Ernst & Young LLP and left the firm in 2009. From 2009 to 2012, he worked as Corporate Finance Manager with ICH Group Limited. From 2013 to 2016, he served as Vice President in Auscar Wealth Management Sdn Bhd, a Malaysian company, responsible for IPOs corporate finance, fund raising, merger and acquisition. From 2019 to 2020, he worked as Group Chief Financial Officer in Nova Group Holdings Limited (whose shares were previously listed on the Stock Exchange with the then stock code: 1360), responsible for the group financial affairs, corporate financial activities, merger & acquisition and corporate restructurings. From 2020 to 2024, Mr. Che worked as Vice President and Chief Financial Officer of Central New Energy Holding Group Limited (whose shares are listed on the Stock Exchange with stock code: 1735). From 2019 to 2023, He served as Chief Financial Officer, Secretary & Executive Director at Next Technology Holdings (Nasdaq: NXTT). In 2024, he served as independent Director at Intelligence Group Limited (Nasdaq: INTJ). Mr. Che is a member of CPA Australia and graduated from the University of Adelaide in Australia and majored in Accounting and Finance in 2005.

Mr. Che has entered into an employment contract with the Company in relation to his position as the Chief Financial Officer, where he will be entitled to a salary of HK\$100,000 per month which was determined with reference to, among other things, his background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions.

The Board would like to extend its warm welcome to Mr. Che on his appointment as Chief Financial Officer.

By Order of the Board  
**TATA Health International Holdings Limited**  
**Zhang Ming Qi**  
*Executive Director*

Hong Kong, 21 October 2025

*As at the date of this announcement, the Board comprises an executive Director, namely, Mr. Zhang Ming Qi; two non-executive Directors, namely, Mr. Chu Chun Ho, Dominic and Mr. Chen Qi; and four independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang, Mr. Du Jianfeng and Mr. Tan Kaiguo.*